SSY Group (HKG:2005) obtained approval from China's National Medical Products Administration for the addition of a 0.5g specification to its Paracetamol tablets, a Friday bourse filing said.
The Chinese regulator has also approved both the 0.3g and 0.5g variants of the Paracetamol tablets as passing the consistency evaluation of the quality and efficacy of generic drugs.
The Paracetamol tablet is mainly used for fever caused by common cold or influenza, as well as for the relief of mild to moderate pain.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.